Whalesbook
Neuland Laboratories Reports Record Q4 Driven by CMS, Higher Full-Year Margin
Q4 Performance Fueled by Commercial CMS Projects
Neuland Laboratories posted a record total income of INR 788.7 crores in Q4 FY26, marking a substantial 134.9% increase year-on-year. This remarkable growth was primarily driven by commercial Contract Manufacturing Services (CMS) projects, which accounted for over two-thirds of the quarter's revenue. The company achieved a robust EBITDA margin of 40.5% in the fourth quarter, reflecting strong operational performance. For the full fiscal year 2026, the EBITDA margin saw a significant improvement, reaching 29.4% compared to 22.9% in the previous year.
Financials: Capex, Working Capital, and Cash Flow
The company's financial results also highlighted substantial capital expenditure of INR 397.1 crores during FY26. This investment, coupled with an increase in working capital, led to negative free cash flow of INR 49.4 crores for the quarter. Working capital days rose to 137 days from 107 days in the prior year, attributed to higher levels of inventories and receivables. Management anticipates normalization of these working capital levels in FY27.
Strategic Growth and Future Expansion
The strong revenue acceleration and improved profitability underscore Neuland's successful ramp-up of its commercial manufacturing services. Strategic investments, including the planned operationalization of its new peptide facility by July 2026, are positioning the company for expansion in the high-growth peptide Contract Development and Manufacturing Organization (CDMO) market. Neuland Laboratories operates as a pharmaceutical company focused on Active Pharmaceutical Ingredients (API) manufacturing and CDMO services for global markets, with a strategic emphasis on complex chemistries and commercial CMS.
Key Risks and Investor Watchpoints
Management has explicitly cautioned investors about the inherent "lumpiness" in quarterly revenue streams, which are project-based. This uneven nature means investors should focus on multi-quarter trends rather than short-term fluctuations. Additionally, higher freight costs, partly exacerbated by geopolitical events in the Middle East, impacted year-end results. The significant increase in working capital days remains a key area for close monitoring.
Competitive Landscape
Neuland's focus on CDMO and API manufacturing places it alongside industry players such as Divi's Laboratories, known for its large-scale API business, Laurus Labs, which is expanding its CDMO offerings, and Granules India, active in API and finished dosage forms. Neuland's strategic push into peptides and its commercial CMS capabilities serve as key differentiators in its growth trajectory.